T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2111)	6/11/2003 10:10:54 AM
From: Icebrg	Read Replies (1) of 2243

>>SPPI - Spectrum Pharmaceuticals>> [And now we know a little bit more about yesterday's price rise. Note, however that in this indication a complete response should more or less be the norm. The tumor is first surgically removed and then chemo or bacillus calmette (!) is injected to take care of whatever that was left behind by the knife. But still, positive news. Erik] Spectrum Reports Positive Phase 1 Data; Will Initiate Phase 2 Study of Eoquin(TM) in Superficial Bladder Cancer Wednesday June 11, 10:00 am ET Complete Response Reported by Investigator in All Five Patients Treated in Phase 1 Eoquin(TM) was Well Tolerated With no Systemic Toxicity IRVINE, Calif., June 11 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI - News) today reported a complete response in each of the first five patients treated with its superficial bladder cancer drug, Eoquin. Patients received six increasing doses of Eoquin over a period of six weeks, which, in each case, resulted in the complete disappearance of the tumors. The response was confirmed by biopsy, and follow-up to determine ongoing remission continues. Message 19022119

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next